Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories reported strong full-year results for FY26 with consolidated revenue from operations of Rs 2,02,299 lakhs, up 37% from Rs 1,47,684 lakhs in FY25. Profit after tax grew 40% to Rs 36,400 lakhs from Rs 26,011 lakhs, while EPS improved to Rs 283.71 from Rs 202.74. The auditors issued an unmodified opinion confirming clean financials. The Board recommended a final dividend of Rs 34 per share (340%) and approved a Rs 143.4 crore capacity expansion at Unit 1 to add 120.5 KL over 12-18 months. An exceptional gain of Rs 7,640 lakhs from investment property sale was recorded. The company also appointed Dr. Mauricio Futran as Additional Director.
The 37% revenue growth and 40% PAT growth reflect strong operational performance across geographies, particularly in Europe and USA. The clean audit opinion and capacity expansion signal confidence in sustained growth, which is positive for shareholders.